Valion Bio Inc (VBIO) Stock Analysis
Verdict: AVOID
Severe burn rate and $1.14M micro-cap status make VBIO a high-dilution trading vehicle rather than a buy-and-hold thesis.
Investment score: 18/100
Analysis as of
Is Valion Bio Inc stock worth reviewing? AI model thesis
The AI model views VBIO as a speculative micro-cap with significant dilution risk, weak revenue scale ($382k in 2025), and negative operating cash flows of -$0.98M.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 10/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 10/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Valion Bio Inc opportunities and risks
What speaks for VBIO
- Late-stage TLR5 agonist asset (Entolimod) targeting Acute Radiation Syndrome
What speaks against VBIO
- Imminent secondary equity dilution risk within 12 months
Frequently asked questions about Valion Bio Inc (VBIO)
Is VBIO stock a good investment?
The cached TradeMates AI model rates Valion Bio Inc as AVOID with an investment score of 18/100. The AI model views VBIO as a speculative micro-cap with significant dilution risk, weak revenue scale ($382k in 2025), and negative operating cash flows of -$0.98M. This is algorithmic model output, not personal investment advice.
Is VBIO stock a buy?
The TradeMates model verdict for VBIO is AVOID with an investment score of 18/100. Treat this as a model signal to review, not a personal buy recommendation.